SG11202000321PA - Cd38 modulating antibody - Google Patents

Cd38 modulating antibody

Info

Publication number
SG11202000321PA
SG11202000321PA SG11202000321PA SG11202000321PA SG11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA
Authority
SG
Singapore
Prior art keywords
stevenage
tusk
catalyst
international
therapeutics
Prior art date
Application number
SG11202000321PA
Inventor
Anne Goubier
Josephine Salimu
Corzo Beatrix Goyenechea
Pascal Merchiers
Kevin Moulder
Nina Eissler
Simone Filosto
Hemanta Baruah
Bianka Prinz
Original Assignee
Black Belt Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2018/065237 external-priority patent/WO2018224682A1/en
Application filed by Black Belt Therapeutics Ltd filed Critical Black Belt Therapeutics Ltd
Publication of SG11202000321PA publication Critical patent/SG11202000321PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) vitivio VIII oviolo Hu vimIE (19) World Intellectual Property Organization International Bureau (10) International Publication Number WO 2019/034752 Al (43) International Publication Date 21 February 2019 (21.02.2019) WIP0 I PCT ited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). MOULDER, Kevin; c/o Tusk Therapeutics Limited, Stevenage Bio- science Catalyst, Gunnels Wood Road, Stevenage Hertford- shire SG1 2FX (GB). EISSLER, Nina; c/o Tusk Therapeu- tics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). FILOSTO, Simone; c/o Tusk Therapeutics Limited, Stevenage Bio- science Catalyst, Gunnels Wood Road, Stevenage Hertford- shire SG1 2FX (GB). BARUAH, Hemanta; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). PRINZ, Bianka; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). (74) Agent: LEONARD, Thomas Charles; Kilburn & Strode LLP, Lacon London, 84 Theobalds Road, London London WC1X 8NL (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (51) International Patent Classification: CO7K 16/28 (2006.01) A61P 35/00 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/EP2018/072271 (22) International Filing Date: 16 August 2018 (16.08.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/546,322 16 August 2017 (16.08.2017) US 62/582,653 07 November 2017 (07.11.2017) US 62/582,666 07 November 2017 (07.11.2017) US PCT/EP2018/065237 08 June 2018 (08.06.2018) EP (71) Applicant: TUSK THERAPEUTICS LTD [GB/GB]; Stevenage Bioscience Catalyst, Accelerator Building, Gun- nels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). (72) Inventors: GOUBIER, Anne; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). SALIMU, Josephine; c/o Tusk Therapeutics Limited, Stevenage Bio- science Catalyst, Gunnels Wood Road, Stevenage Hert- fordshire SG1 2FX (GB). GOYENECHEA, Beatriz; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). MERCHIERS, Pascal; c/o Tusk Therapeutics Lim- (54) Title: CD38 MODULATING ANTIBODY 2000- -• Vehicle DARA aCD38-a-323 0 ; 1500- E e e N .N 1 1000- co L a E H 500- 1-1 It) N O C\ O 1-1 C•1 O 0 14 17 21 24 28 31 days after tumour inoculation (57) : The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer. [Continued on next page] WO 2019/034752 Al 11111111111111111110101011111011111111111111111111111111011111111111111111111111111111111 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11202000321PA 2017-08-16 2018-08-16 Cd38 modulating antibody SG11202000321PA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762546322P 2017-08-16 2017-08-16
US201762582653P 2017-11-07 2017-11-07
US201762582666P 2017-11-07 2017-11-07
PCT/EP2018/065237 WO2018224682A1 (en) 2017-06-08 2018-06-08 Cd38 modulating antibody
PCT/EP2018/072271 WO2019034752A1 (en) 2017-08-16 2018-08-16 Cd38 modulating antibody

Publications (1)

Publication Number Publication Date
SG11202000321PA true SG11202000321PA (en) 2020-02-27

Family

ID=65361804

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000321PA SG11202000321PA (en) 2017-08-16 2018-08-16 Cd38 modulating antibody

Country Status (9)

Country Link
US (1) US20230089373A1 (en)
EP (1) EP3668896A1 (en)
JP (1) JP7224338B2 (en)
KR (1) KR20200036860A (en)
CN (1) CN111032693B (en)
AU (1) AU2018316521A1 (en)
CA (1) CA3073085A1 (en)
SG (1) SG11202000321PA (en)
WO (1) WO2019034752A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114437215B (en) * 2020-11-05 2023-02-07 上海麦济生物技术有限公司 Anti-human CD38 antibody and preparation method and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125640A2 (en) * 2005-05-24 2006-11-30 Morphosys Ag Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
EA037929B1 (en) 2005-03-23 2021-06-08 Генмаб А/С Antibodies against human cd38 and use thereof
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
DK3124497T3 (en) 2007-09-14 2020-05-11 Adimab Llc RATIONALE DESIGNED SYNTHETIC ANTIBODY LIBRARIES AND APPLICATIONS THEREOF
EA026336B1 (en) 2009-09-22 2017-03-31 Пробиоген Аг Vertebrate or insect cell for producing a protein or lipid lacking fucose or having a reduced amount of fucose and uses thereof
JP6266343B2 (en) 2010-07-16 2018-01-24 アディマブ， エルエルシー Antibody library
JOP20210044A1 (en) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co Anti-cd38 antibodies
GB201506389D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates

Also Published As

Publication number Publication date
CN111032693B (en) 2023-09-26
US20230089373A1 (en) 2023-03-23
EP3668896A1 (en) 2020-06-24
CN111032693A (en) 2020-04-17
WO2019034752A1 (en) 2019-02-21
CA3073085A1 (en) 2019-02-21
AU2018316521A1 (en) 2020-02-13
JP2020531003A (en) 2020-11-05
KR20200036860A (en) 2020-04-07
JP7224338B2 (en) 2023-02-17

Similar Documents

Publication Publication Date Title
SG11201908578YA (en) Fc-optimized anti-cd25 for tumour specific cell depletion
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201907848YA (en) Antibodies binding to vista at acidic ph
SG11201901899PA (en) Bispecific trivalent antibodies binding to claudin6 or claudin18.2 and cd3 for treatment of claudin expressing cancer diseases
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201806992VA (en) Antibodies to tigit
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201803956UA (en) Anti-dr5 antibodies and methods of use thereof
SG11201810933QA (en) Anti-c5 antibodies and uses thereof
SG11201908994RA (en) Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
SG11201907299XA (en) Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201906386XA (en) Combination therapy involving diaryl macrocyclic compounds
SG11201809064QA (en) Chimeric neurotoxins
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201807187XA (en) Binding members to pd-l1
SG11201909322VA (en) Treatment of asthma with anti-tslp antibody
SG11201907855QA (en) Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201808125RA (en) Methods for solid tumor treatment
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same